126 related articles for article (PubMed ID: 31092813)
1. Fc receptor-like 2 (FCRL2) is a novel marker of low-risk CLL and refines prognostication based on IGHV mutation status.
Shea LK; Honjo K; Redden DT; Tabengwa E; Li R; Li FJ; Shakhmatov M; Chiorazzi N; Davis RS
Blood Cancer J; 2019 May; 9(6):47. PubMed ID: 31092813
[No Abstract] [Full Text] [Related]
2. FCRL2 mRNA expression is inversely associated with clinical progression in chronic lymphocytic leukemia.
Nückel H; Collins CH; Frey UH; Sellmann L; Dürig J; Siffert W; Dührsen U
Eur J Haematol; 2009 Dec; 83(6):541-9. PubMed ID: 19682311
[TBL] [Abstract][Full Text] [Related]
3. FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia.
Li FJ; Ding S; Pan J; Shakhmatov MA; Kashentseva E; Wu J; Li Y; Soong SJ; Chiorazzi N; Davis RS
Blood; 2008 Jul; 112(1):179-87. PubMed ID: 18314442
[TBL] [Abstract][Full Text] [Related]
4. Analysis of LPL gene expression in patients with chronic lymphocytic leukemia.
Bilous N; Abramenko I; Chumak A; Dyagil I; Martina Z
Exp Oncol; 2019 Mar; 41(1):39-45. PubMed ID: 30932419
[TBL] [Abstract][Full Text] [Related]
5. High CXCR3 on Leukemic Cells Distinguishes
Manukyan G; Papajik T; Mikulkova Z; Urbanova R; Kraiczova VS; Savara J; Kudelka M; Turcsanyi P; Kriegova E
J Immunol Res; 2020; 2020():7084268. PubMed ID: 32802894
[TBL] [Abstract][Full Text] [Related]
6. Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia.
Sandoval-Sus JD; Chavez JC; Dalia S; Naqvi SMH; Talati C; Nodzon L; Kharfan-Dabaja MA; Pinilla-Ibarz J
Leuk Lymphoma; 2018 Jan; 59(1):59-68. PubMed ID: 28641468
[TBL] [Abstract][Full Text] [Related]
7. Targeted deep sequencing reveals clinically relevant subclonal IgHV rearrangements in chronic lymphocytic leukemia.
Stamatopoulos B; Timbs A; Bruce D; Smith T; Clifford R; Robbe P; Burns A; Vavoulis DV; Lopez L; Antoniou P; Mason J; Dreau H; Schuh A
Leukemia; 2017 Apr; 31(4):837-845. PubMed ID: 27795555
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials.
Wojdacz TK; Amarasinghe HE; Kadalayil L; Beattie A; Forster J; Blakemore SJ; Parker H; Bryant D; Larrayoz M; Clifford R; Robbe P; Davis ZA; Else M; Howard DR; Stamatopoulos B; Steele AJ; Rosenquist R; Collins A; Pettitt AR; Hillmen P; Plass C; Schuh A; Catovsky D; Oscier DG; Rose-Zerilli MJJ; Oakes CC; Strefford JC
Blood Adv; 2019 Aug; 3(16):2474-2481. PubMed ID: 31434681
[TBL] [Abstract][Full Text] [Related]
9. Another step forward in the 20-year history of
Giudice ID; Foà R
Haematologica; 2019 Feb; 104(2):219-221. PubMed ID: 30705114
[No Abstract] [Full Text] [Related]
10. Elevated miR-20b-5p expression in peripheral blood mononuclear cells: A novel, independent molecular biomarker of favorable prognosis in chronic lymphocytic leukemia.
Papageorgiou SG; Kontos CK; Tsiakanikas P; Stavroulaki G; Bouchla A; Vasilatou D; Bazani E; Lazarakou A; Scorilas A; Pappa V
Leuk Res; 2018 Jul; 70():1-7. PubMed ID: 29715621
[TBL] [Abstract][Full Text] [Related]
11. Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia.
Visco C; Moretta F; Falisi E; Facco M; Maura F; Novella E; Nichele I; Finotto S; Giaretta I; Ave E; Perbellini O; Guercini N; Scupoli MT; Trentin L; Trimarco V; Neri A; Semenzato G; Rodeghiero F; Pizzolo G; Ambrosetti A
Am J Hematol; 2013 Apr; 88(4):277-82. PubMed ID: 23450508
[TBL] [Abstract][Full Text] [Related]
12. Stereotyped subset #1 chronic lymphocytic leukemia: a direct link between B-cell receptor structure, function, and patients' prognosis.
Del Giudice I; Chiaretti S; Santangelo S; Tavolaro S; Peragine N; Marinelli M; Ilari C; Raponi S; Messina M; Nanni M; Mauro FR; Piciocchi A; Bontempi K; Rossi D; Gaidano G; Guarini A; Foà R
Am J Hematol; 2014 Jan; 89(1):74-82. PubMed ID: 24030933
[TBL] [Abstract][Full Text] [Related]
13. Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations.
Baliakas P; Agathangelidis A; Hadzidimitriou A; Sutton LA; Minga E; Tsanousa A; Scarfò L; Davis Z; Yan XJ; Shanafelt T; Plevova K; Sandberg Y; Vojdeman FJ; Boudjogra M; Tzenou T; Chatzouli M; Chu CC; Veronese S; Gardiner A; Mansouri L; Smedby KE; Pedersen LB; Moreno D; Van Lom K; Giudicelli V; Francova HS; Nguyen-Khac F; Panagiotidis P; Juliusson G; Angelis L; Anagnostopoulos A; Lefranc MP; Facco M; Trentin L; Catherwood M; Montillo M; Geisler CH; Langerak AW; Pospisilova S; Chiorazzi N; Oscier D; Jelinek DF; Darzentas N; Belessi C; Davi F; Ghia P; Rosenquist R; Stamatopoulos K
Blood; 2015 Jan; 125(5):856-9. PubMed ID: 25634617
[TBL] [Abstract][Full Text] [Related]
14. Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study.
Bomben R; Dal Bo M; Capello D; Forconi F; Maffei R; Laurenti L; Rossi D; Del Principe MI; Zucchetto A; Bertoni F; Rossi FM; Bulian P; Cattarossi I; Ilariucci F; Sozzi E; Spina V; Zucca E; Degan M; Lauria F; Del Poeta G; Efremov DG; Marasca R; Gaidano G; Gattei V
Br J Haematol; 2009 Feb; 144(4):492-506. PubMed ID: 19036101
[TBL] [Abstract][Full Text] [Related]
15. UGT2B17 expression: a novel prognostic marker within IGHV-mutated chronic lymphocytic leukemia?
Bhoi S; Baliakas P; Cortese D; Mattsson M; Engvall M; Smedby KE; Juliusson G; Sutton LA; Mansouri L
Haematologica; 2016 Feb; 101(2):e63-5. PubMed ID: 26589911
[No Abstract] [Full Text] [Related]
16. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
Spunarova M; Tom N; Pavlova S; Mraz M; Brychtova Y; Doubek M; Panovska A; Skuhrova Francova H; Brzobohata A; Pospisilova S; Mayer J; Trbusek M
Leuk Res; 2019 Jun; 81():75-81. PubMed ID: 31054420
[TBL] [Abstract][Full Text] [Related]
17. Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical features.
Morabito F; Mosca L; Cutrona G; Agnelli L; Tuana G; Ferracin M; Zagatti B; Lionetti M; Fabris S; Maura F; Matis S; Gentile M; Vigna E; Colombo M; Massucco C; Recchia AG; Bossio S; De Stefano L; Ilariucci F; Musolino C; Molica S; Di Raimondo F; Cortelezzi A; Tassone P; Negrini M; Monti S; Rossi D; Gaidano G; Ferrarini M; Neri A
Clin Cancer Res; 2013 Nov; 19(21):5890-900. PubMed ID: 24036852
[TBL] [Abstract][Full Text] [Related]
18. Double IGHV DNA gene rearrangements in CLL: influence of mixed-mutated and -unmutated rearrangements on outcomes in CLL.
Heyman B; Volkheimer AD; Weinberg JB
Blood Cancer J; 2016 Jul; 6(7):e440. PubMed ID: 27367477
[No Abstract] [Full Text] [Related]
19. Clinical significance of down-regulated cylindromatosis gene in chronic lymphocytic leukemia.
Wu W; Zhu H; Fu Y; Shen W; Xu J; Miao K; Hong M; Xu W; Liu P; Li J
Leuk Lymphoma; 2014 Mar; 55(3):588-94. PubMed ID: 23725390
[TBL] [Abstract][Full Text] [Related]
20. The Light Chain IgLV3-21 Defines a New Poor Prognostic Subgroup in Chronic Lymphocytic Leukemia: Results of a Multicenter Study.
Stamatopoulos B; Smith T; Crompot E; Pieters K; Clifford R; Mraz M; Robbe P; Burns A; Timbs A; Bruce D; Hillmen P; Meuleman N; Mineur P; Firescu R; Maerevoet M; De Wilde V; Efira A; Philippé J; Verhasselt B; Offner F; Sims D; Heger A; Dreau H; Schuh A
Clin Cancer Res; 2018 Oct; 24(20):5048-5057. PubMed ID: 29945996
[No Abstract] [Full Text] [Related]
[Next] [New Search]
